Litcius/Paper detail

Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial

J. Connor Wells, Monica M. Mullin, Cheryl Ho, Barbara Melosky, Janessa Laskin, Ying Wang, Sophie Sun

2024Lung Cancer10 citationsDOI

Topics & Concepts

MedicineOsimertinibInternal medicineLung cancerPopulationT790MClinical trialOncologyCohortCancerSurgeryEpidermal growth factor receptorGefitinibErlotinibEnvironmental healthLung Cancer Treatments and MutationsLung Cancer Research StudiesAdvanced Breast Cancer Therapies
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial | Litcius